Share-Based Stock Options for Directors
First written in FY2019-Q1. 3 of 7 entries say "Restated". Latest entry: FY2023.
- FY2023RestatedAnnual report
「Stock acquisition rights as 2018 stock options, stock acquisition rights as 2019 stock options, stock acquisition rights as 2020 stock options, stock acquisition rights as 2021 stock options」
The company continues to disclose the existing four fiscal-year grants of share-based compensation stock options for directors. No new grants or exercises were disclosed for the current period. - FY2021AdvancedAnnual report
「At a meeting of the Board of Directors held on 22 June 2021, the company resolved, pursuant to Articles 236, 238 and 240 of the Companies Act, matters concerning the offering of stock acquisition rights to be allotted to directors as share-based compensation stock options.」
On 22 June 2021, the company resolved the offering terms for allotting 2,155 stock acquisition rights, each covering 10 shares, to 6 directors, excluding outside directors. The exercise period is from 31 July 2021 to 30 July 2051. - FY2021-Q2AdvancedAnnual report
「The company’s directors (excluding outside directors): 4 Number of stock acquisition rights: 1,112 Class, description and number of shares underlying the stock acquisition rights: Common shares, 11,120 shares (Note 1) Exercise period for the stock acquisition rights: 1 August 2020 to 31 July 2050」
Based on a resolution dated 30 June 2020, new share-based compensation stock options covering 11,120 common shares were granted to 4 directors, excluding outside directors. - FY2020-Q2AdvancedAnnual report
「The company’s directors (excluding outside directors): 4 Number of stock acquisition rights: 740 Class, description and number of shares underlying the stock acquisition rights: Common shares, 7,400 shares (Note 1) Exercise period for the stock acquisition rights: 1 August 2019 to 31 July 2049」
Based on a resolution dated 21 June 2019, new share-based compensation stock options covering 7,400 common shares were granted to 4 directors, excluding outside directors. - FY2019RestatedAnnual report
「Stock acquisition rights covering 5,240 common shares were granted to 4 of the company’s directors, excluding outside directors, with an exercise period from 1 August 2018 to 31 July 2048.」
The company continues to disclose the share-based compensation stock options covering 5,240 shares for 4 directors, including their exercise conditions and period. - FY2019-Q2RestatedAnnual report
「The company’s directors (excluding outside directors): 4 Class and number of shares underlying the stock acquisition rights Common shares of the company: 5,240 shares Exercise period for the stock acquisition rights 1 August 2018 to 31 July 2048」
The company continues to disclose the existing grant details and exercise period for share-based compensation stock options covering 5,240 shares for 4 directors. - FY2019-Q1First statedAnnual report
「The company’s directors (excluding outside directors): 4 Class and number of shares underlying the stock acquisition rights Common shares of the company: 5,240 shares Exercise period for the stock acquisition rights 1 August 2018 to 31 July 2048」
Based on a resolution of the Board of Directors dated 22 June 2018, stock options in the form of share-based compensation covering 5,240 shares were established for 4 directors, excluding outside directors. The exercise period is from 1 August 2018 to 31 July 2048, and exercise is permitted upon the loss of director status.